DOCSLIB.ORG

New Apis and Impurity Reference Standards 2015 Acecarbromal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Apis and Impurity Reference Standards 2015 Acecarbromal New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Acecarbromal O O O Br MM1724.00 Acecarbromal 77-66-7 A 50mg N N H H Acefylline O O OH N MM1727.00 Acefylline 652-37-9 A 250mg N O N N Acenocoumarol O O O N + O MM1205.00 Acenocoumarol 152-72-7 A 250mg OH O Acetaminosalol H N O O MM1609.00 Acetaminosalol 118-57-0 A 250mg O OH Acetophenazine Maleate O N N OH S N MM1725.00 Acetophenazine Maleate 5714-00-1 A 100mg OH OH O O 2 Adapalene Br MM0681.05 Methyl 6-Bromo-2-naphthoate 33626-98-1 A 100mg O O O Methyl 6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoate MM0681.06 106685-41-0 A 100mg (Adapalene Methyl Ester) O O Adenine N H 2 H N MM1495.00 Adenine 73-24-5 A 250mg N N N Adrenaline Tartrate OH H MM0614.12 DL-Adrenaline Hydrochloride 329-63-5 A 250mg H O N HCl H O Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Alanine N H Imp. B (EP): (2S)-2-Aminopentanedioic Acid (Glutamic 2 MM1333.00 56-86-0 A 250mg H O OH Acid) O O Ambutonium Bromide O N H2 Br MM1780.00 Ambutonium Bromide 115-51-5 A 100mg + N Amiloride Hydrochloride O Imp. A (EP): Methyl 3,5-Diamino-6- Cl N MM0560.01 1458-01-1 A 100mg O chloropyrazine-2-carboxylate H2 N N N H2 Aminotadalafil O H N H N 2 N N H MM1271.00 Aminotadalafil 385769-84-6 A 100mg O O O Amitriptyline Hydrochloride (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene) O MM0062.15 3707-33-3 A 100mg acetic Acid OH Amotriphene Hydrochloride O N MM3021.00 Amotriphene Hydrochloride 568-69-4 A 50mg HCl O O Aripiprazole N H Imp. B (EP) as Hydrochloride: 1-(2,3-Dichlorophenyl) N MM0961.02 119532-26-2 A 100mg HCl piperazine Hydrochloride Cl Cl H O N O Imp. E (EP): 7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl] N MM0961.04 129722-25-4 A 100mg N butoxy]quinolin-2(1H)-one Cl Cl Articaine Hydrochloride O O H N HCl MM0369.00 Articaine Hydrochloride 23964-57-0 A 250mg N S H O Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Atovaquone Cl O MM3007.00 Atovaquone 95233-18-4 A 250mg OH O Azacitidine O O O O O MM1259.03 1-O-Acetyl-2,3,5-tri-O-benzoyl-ß-D-ribofuranose 6974-32-9 A 100mg O O O O Azaperone F N MM1164.00 Azaperone 1649-18-9 A 250mg O N N Azathioprine O + N N O MM1532.00 Azathioprine 446-86-6 A 250mg N S H N N N N Bamethan Sulfate OH H N O O H O S MM1822.00 Bamethan Sulfate 5716-20-1 A 100mg H O OH OH H N H O Bazedoxifene Acetate HO OH N MM3342.00 Bazedoxifene Acetate 198481-33-3 A 50mg O OH N O Bendamustine Hydrochloride O O 5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole- N MM0154.02 3543-74-6 A 100mg H O 2-butanoic Acid Ethyl Ester N N H O O 1-Methyl-5-amino-1H-benzimidazole-2-butanoic Acid Ethyl O MM0154.03 3543-73-5 A 100mg N Ester N H2 N Bendroflumethiazide O O O O S S H2 N N H MM0674.00 Bendroflumethiazide 73-48-3 A 100mg F N F F H Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Benperidol O H N Mixture of Imp. D and E (EP): Benperidol N-Oxide (cis N O MM0113.09 118435-01-1 A 25mg + N and trans) O F Benzethonium Chloride + O N MM1425.00 Benzethonium Chloride 121-54-0 A 250mg O Cl Benzthiazide O O O O S S MM1716.00 Benzthiazide 91-33-8 A 50mg H 2N N H S Cl N Benzylpenicillin Procaine O O O OH O N N H H2O MM0302.00 Benzylpenicillin Procaine 6130-64-9 A 250mg N S H O N H 2 Betamethasone O OH Imp. E (EP): 9,11 -Epoxy-17,21-dihydroxy-16 -methyl-9 - OH MM0200.04 981-34-0 A 100mg O pregna-1,4-diene-3,20-dione H H O Biphenamine Hydrochloride OH O N HCl MM1877.00 Biphenamine Hydrochloride 5560-62-3 A 100mg O Bis(2-ethylhexyl) Maleate MM2104.00 Bis(2-ethylhexyl) Maleate 142-16-5 A 250mg O O O O Bisoctrizole N OH N N MM3255.01 2-(2H-Benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol 3147-75-9 A 100mg Bitoscanate N C S S MM1837.00 Bitoscanate 4044-65-9 A 250mg C N Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Bosentan Monohydrate O O S N H O O N H2O MM3369.00 Bosentan Monohydrate 157212-55-0 A 250mg N N O N OH Bromocriptine Mesilate Br H N O H O H N N N H N MM1159.00 Bromocriptine Mesilate 22260-51-1 A 100mg O O OH O O S OH Butafosfan O H H N P MM3311.00 Butafosfan 17316-67-5 A 250mg OH Butalamine Hydrochloride H N O N N N MM1845.00 Butalamine Hydrochloride 56974-46-0 A 50mg HCl Butamben O MM1802.00 Butamben 94-25-7 A 250mg O H 2N Butoconazole Nitrate Cl O + MM1637.00 Butoconazole Nitrate 64872-77-1 A 250mg Cl S N HO O N Cl N Calcium Dobesilate Monohydrate H O MM0632.01 Imp. A (EP): Benzene-1,4-diol (Hydroquinone) 123-31-9 A 100mg OH Calcium Folinate O O O 2+ Ca H O O N H MM0324.00 Calcium Folinate 1492-18-8 A 250mg N O N N H O H 2N N N H H Calcium Pantothenate O O HO 2+ MM1499.00 Calcium Pantothenate 137-08-6 A 250mg N O Ca H OH 2 Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Carbidopa O OH H2 O MM1501.00 Carbidopa 38821-49-7 A 250mg H N H O N H2 OH Carbimazole MM1748.00 Carbimazole 22232-54-8 A 250mg N N O S O Carprofen H N MM1484.01 Carbazole 86-74-8 A 100mg Carvedilol OH H Imp. D (EP): 1-(9H-Carbazol-4-yloxy)-3-[4-[2-hydroxy-3- O N O O H O MM0291.13 [[2-(2-methoxyphenoxy)ethyl]amino]propoxy]-9H-carbazol- 1391052-16-6 D 100mg N O 9-yl]propan-2-ol H N H 2N O MM0291.09 2-(2-Methoxyphenoxy)ethylamine 1836-62-0 A 100mg O Cefadroxil Monohydrate O OH O N H2 N H H2 O MM0972.00 Cefadroxil Monohydrate 66592-87-8 A 250mg N S H O H O Cefepime Dihydrochloride Monohydrate O O O O + HCl N N N MM1475.00 Cefepime Dihydrochloride Monohydrate 123171-59-5 A 250mg H 2 N N H2O S H 2N H H S O Cefradine O OH O N H N 2 H MM0833.00 Cefradine 38821-53-3 A 250mg N S H O Cetrimide + MM0876.00 Cetrimide 1119-97-7 A 250mg N Br Chloral Betaine OH O Cl + MM1752.00 Chloral Betaine 2218-68-0 A 100mg OH N O Cl Cl Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Chloralose H H O O O Cl MM2538.00 Chloralose 15879-93-3 A 250mg Cl H O H O Cl H O H Chlorzoxazone O MM0908.00 Chlorzoxazone 95-25-0 A 250mg O Cl N H OH MM0908.01 2-Amino-4-chlorophenol 95-85-2 A 100mg Cl N H2 Ciclopirox Olamine Imp. B (EP): 6-Cyclohexyl-4-methyl-2H- O O MM0418.02 14818-35-0 A 100mg pyran-2-one Cinacalcet Hydrochloride F F N F MM3370.00 Cinacalcet Hydrochloride 364782-34-3 A 100mg H HCl Cineole MM1763.00 Cineole 470-82-6 A 250mg O Cinnamedrine Hydrochloride OH MM1992.00 Cinnamedrine Hydrochloride 25441-16-1 A 50mg N HCl Cinnarizine N MM1038.00 Cinnarizine 298-57-7 A 250mg N Clidinium Bromide OH MM1798.00 Clidinium Bromide 3485-62-9 A 100mg O Br O + N Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Clindamycin Palmitate Hydrochloride OH H Cl OH O O H N O H O MM1989.00 Clindamycin Palmitate Hydrochloride 25507-04-4 A 250mg N S HCl Clindamycin Phosphate N Cl H N O O MM1520.00 Clindamycin Phosphate 24729-96-2 A 250mg H O S O H O O P OH OH Clorgyline Hydrochloride Cl HCl MM3019.00 Clorgyline Hydrochloride 17780-75-5 A 50mg O N Cl Clorsulon O O O O S S H 2N N H2 MM1518.00 Clorsulon 60200-06-8 A 250mg Cl N H2 Cl Cl Cycloguanil Embonate Cl N N H2 N N N H 2 MM3025.00 Cycloguanil Embonate 609-78-9 A 50mg 2 O OH OH O H O OH Cycloguanil Hydrochloride Cl MM1580.00 Cycloguanil Hydrochloride 152-53-4 A 100mg N N HCl H 2N N N H2 Cyclophosphamide Cl O O P N H O MM0822.00 Cyclophosphamide Monohydrate 6055-19-2 A 250mg 2 N H Cl Dantrolene Sodium O MM0905.01 5-(4-Nitrophenyl)furan-2-carbaldehyde 7147-77-5 A 100mg O O + N O Dantrolene Sodium Hydrate O N N O N + Na H2O O + MM3086.00 Dantrolene Sodium Hydrate 24868-20-0 A 250mg N 2 7 O O 2 Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No.
Load more

Recommended publications
  • Roger Lee Papke Box 100267 JHM Health Science Center Gainesville, Florida 32610
    CURRICULUM VITAE Roger Lee Papke DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS UNIVERSITY OF FLORIDA SCHOOL OF MEDICINE Box 100267 J.H.M. Health Science Center Gainesville, Florida 32610 (352) 392-4712, FAX (352) 392-9696 [email protected] BIOGRAPHICAL DATA: Born: October 12, 1953, Kenmore, New York Married: December 24, 1980 to Clare Stokes Citizenship: U. S. A. EDUCATION: Starpoint Central School Pendleton, N. Y. Primary and Secondary N.Y.S. Regents Diploma 1971 New York University Washington Square College of Arts and Sciences 1971 - 1975 Majors in Biology and Classical Civilization Bachelor of Arts awarded May 1975 New York University Graduate school of Arts and Sciences 1975 - 1976 Thesis advisor: Dr. Fleur L. Strand Thesis title: An Alpha Adrenergic Response of Cardiac Muscle at an Alkaline pH Master of Science awarded May 1976 Cornell University Graduate School of Arts and Science 1976-1979: Section of Physiology Graduate Research Assistant in Reproductive Physiology Advisor: Dr. William Hansel Research topic: The endocrine control of delayed implantation in mink Cornell University Graduate School of Arts and Science 1979-1986: Section of Neurobiology and Behavior Thesis Advisor: Dr. Robert Oswald Primary research topic: Pharmacology of nicotinic acetylcholine receptors Thesis Title: The Gating of Single Channel Currents Through the Nicotinic Acetylcholine Receptors of BC3H-1 Cells: Effects of Agonists and Allosteric Ligands Ph.D. conferred January 1987 ACADEMIC APPOINTMENTS: 1987 Postdoctoral Research Associate: Department of Pharmacology,
    [Show full text]
  • Differential Effects of Alkaloids on Memory in Rodents
    www.nature.com/scientificreports OPEN Diferential efects of alkaloids on memory in rodents Patrick M. Callahan1,2, Alvin V. Terry Jr.1,2, Manuel C. Peitsch3, Julia Hoeng3* & Kyoko Koshibu3* Nicotinic acetylcholine receptors (nAChRs) play a critical role in the neuropharmacology of learning and memory. As such, naturally occurring alkaloids that regulate nAChR activity have gained interest for understanding and potentially improving memory function. In this study, we tested the acute efects of three known nicotinic alkaloids, nicotine, cotinine, and anatabine, in suppressing scopolamine-induced memory defcit in rodents by using two classic memory paradigms, Y-maze and novel object recognition (NOR) in mice and rats, respectively. We found that all compounds were able to suppress scopolamine-induced spatial memory defcit in the Y-maze spontaneous alternation paradigm. However, only nicotine was able to suppress the short-term object memory defcit in NOR, despite the higher doses of cotinine and anatabine used to account for their potential diferences in nAChR activity. These results indicate that cotinine and anatabine can uniquely regulate short-term spatial memory, while nicotine seems to have more robust and general role in memory regulation in rodents. Thus, nAChR-activating alkaloids may possess distinct procognitive properties in rodents, depending on the memory types examined. Te cholinergic system of the brain is a critical regulator of attention, memory, and higher-order cognitive processing, and its defcits are central to the etiology of dementia1. As such, nicotinic acetylcholine receptors (nAChRs) have gained much interest as a target of drug development 2. Neuronal nAChRs are pentameric pro- teins composed of various combinations of α (α2–α9) and β (β2–β4) nAChR subunits, diferentially expressed throughout the nervous system.
    [Show full text]
  • Federal Register/Vol. 82, No. 13/Monday, January 23, 2017/Proposed Rules
    8004 Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Proposed Rules DEPARTMENT OF HEALTH AND comment will be made public, you are www.regulations.gov. Submit both HUMAN SERVICES solely responsible for ensuring that your copies to the Division of Dockets comment does not include any Management. If you do not wish your Food and Drug Administration confidential information that you or a name and contact information to be third party may not wish to be posted, made publicly available, you can 21 CFR Part 1132 such as medical information, your or provide this information on the cover [Docket No. FDA–2016–N–2527] anyone else’s Social Security number, or sheet and not in the body of your confidential business information, such comments and you must identify this Tobacco Product Standard for N- as a manufacturing process. Please note information as ‘‘confidential.’’ Any Nitrosonornicotine Level in Finished that if you include your name, contact information marked as ‘‘confidential’’ Smokeless Tobacco Products information, or other information that will not be disclosed except in identifies you in the body of your accordance with 21 CFR 10.20 and other AGENCY: Food and Drug Administration, comments, that information will be applicable disclosure law. For more HHS. posted on http://www.regulations.gov. information about FDA’s posting of • ACTION: Proposed rule. If you want to submit a comment comments to public dockets, see 80 FR with confidential information that you 56469, September 18, 2015, or access SUMMARY: The Food and Drug do not wish to be made available to the the information at: http://www.fda.gov/ Administration (FDA) is proposing a public, submit the comment as a regulatoryinformation/dockets/ tobacco product standard that would written/paper submission and in the default.htm.
    [Show full text]
  • Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence
    Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence By Jiahui Zhang A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Jiahui Zhang (2017) Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence Jiahui Zhang Degree of Master of Science Graduate Department of Pharmacology and Toxicology University of Toronto ABSTRACT Bupropion and varenicline are effective, first-line prescription-only pharmacotherapies for smoking cessation; however, their real-world use is limited by affordability and accessibility. Using a novel internet-based randomized design, we evaluated the real-world effectiveness of mailed bupropion and varenicline, as well as the roles of nicotine metabolism (NMR) and medication adherence, in a sample of interested smokers using web-based recruitment and follow up. Quit rates at end of treatment (EOT) were significantly higher for varenicline (30.2%) compared to bupropion (19.6%). Quit rates at 6 months (14.0%) and 12 months (12.1%) were not significantly different between bupropion and varenicline. Increased medication compliance significantly improved cessation outcomes at EOT. NMR was associated with nicotine dependence. Varenicline benefited Slow Metabolizers of nicotine whilst bupropion benefited Normal Metabolizers. Even though real-world quit rates were comparable to clinical trials, improving medication compliance and implementing personalized pharmacological and behavioral interventions are promising approaches to increase efficacy of smoking cessation pharmacotherapies. ii ACKNOWLEDGEMENTS First and foremost, I would like to express my sincerest appreciation to my supervisor, Dr.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Poisons Act.Fm
    LAWS OF BRUNEI CHAPTER 114 POISONS Enactment No. 13 of 1956 Amended by S 103/1958 Enactment No. 6 of 1967 S 101/1979 1984 Edition, Chapter 114 Amended by S 16/1996 S 28/2001 GN 273/2002 REVISED EDITION 2015 B.L.R.O. 1/2015 LAWS OF BRUNEI Poisons CAP. 114 1 LAWS OF BRUNEI REVISED EDITION 2015 CHAPTER 114 POISONS ARRANGEMENT OF SECTIONS Section 1. Citation. 2. Interpretation. 3. Description of poisons. 4. Licensing Officers. 5. General prohibition with respect to importation and sale of poisons. 6. Prohibitions and provisions relating to sale of poisons. 7. Exemptions in respect of medicines. 8. Exemptions in respect of sale. 9. Possession of poisons. 10. Issue of licences. 11. Different kinds of licence. 12. Licences to be numbered and registered. 13. Annual list to be published. 14. Forms of licence. 15. Search and search warrants. 16. Powers of exemption. 17. Penalties. B.L.R.O. 1/2015 LAWS OF BRUNEI 2 CAP. 114 Poisons 18. Jurisdiction. 19. Prosecutions. 20. Prohibition of sale to persons under 18. 21. Rules. SCHEDULE — POISONS LIST ____________________________ LAWS OF BRUNEI Poisons CAP. 114 3 POISONS ACT An Act to regulate the importation, possession, manufacture, compounding, storage, transport and sale of poisons Commencement: 1st January 1983 [S 61/1957] Citation. 1. This Act may be cited as the Poisons Act. Interpretation. 2. In this Act, unless the context otherwise requires — “dentist” means a dentist licensed under the Medical Practitioners and Dentists Act (Chapter 112) and includes a Government dentist; “export”, in relation
    [Show full text]
  • July 16, 2018 VIA ELECTRONIC SUBMISSION and HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishe
    Jose Luis Murillo Vice President Regulatory Affairs July 16, 2018 VIA ELECTRONIC SUBMISSION AND HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-N-6189 (83 Fed. Reg. 11,818, March 16, 2018) Advance Notice of Proposed Rulemaking on Tobacco Product Standard for Nicotine Level of Certain Tobacco Products Altria Client Services (“ALCS”), on behalf of Philip Morris USA Inc. (“PM USA”), John Middleton Company (“JMC”), and Sherman Group Holdings LLC and its subsidiaries (“Nat Sherman”),1 submits these comments to the Food and Drug Administration’s (“FDA’s” or the “Agency’s”) Advance Notice of Proposed Rulemaking (“ANPRM”) on a Tobacco Product Standard for Nicotine Level of Certain Tobacco Products. The ANPRM comes within the context of an industry in the midst of transformative change. Cigarette smoking is at historically low levels and continues to decline. At the same time, a new market is emerging in innovative noncombustible tobacco products that are potentially less harmful than cigarettes. There is now a scientific consensus that noncombustible products, like e-vapor, are substantially less risky than conventional cigarettes. It is smoke, and not nicotine, that causes most tobacco- related harm. And adult smokers are increasingly expressing interest in switching from cigarettes to less risky alternatives. We agree that a nicotine product standard of some sort may make sense in a future regulatory system, but this requires the pre-existence of a marketplace with alternative, FDA-authorized, reduced risk products; more information about the relative risks of those products; and a regulatory system that respects the rights of adults to make decisions based on accurate information.
    [Show full text]
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]